Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

An additive effect of anti-PAI-1 antibody to ACE inhibitor on slowing the progression of diabetic kidney disease.

Gu C, Zhang J, Noble NA, Peng XR, Huang Y.

Am J Physiol Renal Physiol. 2016 Nov 1;311(5):F852-F863. doi: 10.1152/ajprenal.00564.2015. Epub 2016 Aug 10.

2.

Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function.

Bajaj JS, Cox IJ, Betrapally NS, Heuman DM, Schubert ML, Ratneswaran M, Hylemon PB, White MB, Daita K, Noble NA, Sikaroodi M, Williams R, Crossey MM, Taylor-Robinson SD, Gillevet PM.

Am J Physiol Gastrointest Liver Physiol. 2014 Nov 15;307(10):G951-7. doi: 10.1152/ajpgi.00268.2014. Epub 2014 Sep 25.

3.

Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization.

Patidar KR, Thacker LR, Wade JB, Sterling RK, Sanyal AJ, Siddiqui MS, Matherly SC, Stravitz RT, Puri P, Luketic VA, Fuchs M, White MB, Noble NA, Unser AB, Gilles H, Heuman DM, Bajaj JS.

Am J Gastroenterol. 2014 Nov;109(11):1757-63. doi: 10.1038/ajg.2014.264. Epub 2014 Sep 2.

4.

Effects of obstructive sleep apnea on sleep quality, cognition, and driving performance in patients with cirrhosis.

Bajaj JS, Thacker LR, Leszczyszyn D, Taylor SA, Heuman DM, Raman S, Sterling RK, Siddiqui MS, Stravitz RT, Sanyal AJ, Puri P, Luketic V, Matherly S, Fuchs M, White MB, Noble NA, Unser AB, Wade JB.

Clin Gastroenterol Hepatol. 2015 Feb;13(2):390-397.e1. doi: 10.1016/j.cgh.2014.08.028. Epub 2014 Aug 23.

5.

Validation of EncephalApp, Smartphone-Based Stroop Test, for the Diagnosis of Covert Hepatic Encephalopathy.

Bajaj JS, Heuman DM, Sterling RK, Sanyal AJ, Siddiqui M, Matherly S, Luketic V, Stravitz RT, Fuchs M, Thacker LR, Gilles H, White MB, Unser A, Hovermale J, Gavis E, Noble NA, Wade JB.

Clin Gastroenterol Hepatol. 2015 Oct;13(10):1828-1835.e1. doi: 10.1016/j.cgh.2014.05.011. Epub 2014 May 17.

6.

Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis.

Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, Puri P, Sterling RK, Luketic V, Stravitz RT, Siddiqui MS, Fuchs M, Thacker LR, Wade JB, Daita K, Sistrun S, White MB, Noble NA, Thorpe C, Kakiyama G, Pandak WM, Sikaroodi M, Gillevet PM.

Aliment Pharmacol Ther. 2014 May;39(10):1113-25. doi: 10.1111/apt.12695. Epub 2014 Mar 16.

7.

Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: implications for the gut-liver-brain axis.

Ahluwalia V, Wade JB, Heuman DM, Hammeke TA, Sanyal AJ, Sterling RK, Stravitz RT, Luketic V, Siddiqui MS, Puri P, Fuchs M, Lennon MJ, Kraft KA, Gilles H, White MB, Noble NA, Bajaj JS.

Metab Brain Dis. 2014 Dec;29(4):1017-25. doi: 10.1007/s11011-014-9507-6. Epub 2014 Mar 4.

8.

Altered profile of human gut microbiome is associated with cirrhosis and its complications.

Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, Noble NA, Unser AB, Daita K, Fisher AR, Sikaroodi M, Gillevet PM.

J Hepatol. 2014 May;60(5):940-7. doi: 10.1016/j.jhep.2013.12.019. Epub 2013 Dec 25.

9.

Diagnosis of covert hepatic encephalopathy without specialized tests.

Nabi E, Thacker LR, Wade JB, Sterling RK, Stravitz RT, Fuchs M, Heuman DM, Bouneva I, Sanyal AJ, Siddiqui MS, Luketic V, White MB, Monteith P, Noble NA, Unser A, Bajaj JS.

Clin Gastroenterol Hepatol. 2014 Aug;12(8):1384-1389.e2. doi: 10.1016/j.cgh.2013.12.020. Epub 2013 Dec 19.

10.

Cognitive dysfunction is associated with poor socioeconomic status in patients with cirrhosis: an international multicenter study.

Bajaj JS, Riggio O, Allampati S, Prakash R, Gioia S, Onori E, Piazza N, Noble NA, White MB, Mullen KD.

Clin Gastroenterol Hepatol. 2013 Nov;11(11):1511-6. doi: 10.1016/j.cgh.2013.05.010. Epub 2013 May 22.

11.

Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.

Bajaj JS, Heuman DM, Sanyal AJ, Hylemon PB, Sterling RK, Stravitz RT, Fuchs M, Ridlon JM, Daita K, Monteith P, Noble NA, White MB, Fisher A, Sikaroodi M, Rangwala H, Gillevet PM.

PLoS One. 2013;8(4):e60042. doi: 10.1371/journal.pone.0060042. Epub 2013 Apr 2.

12.

Modulation of the fecal bile acid profile by gut microbiota in cirrhosis.

Kakiyama G, Pandak WM, Gillevet PM, Hylemon PB, Heuman DM, Daita K, Takei H, Muto A, Nittono H, Ridlon JM, White MB, Noble NA, Monteith P, Fuchs M, Thacker LR, Sikaroodi M, Bajaj JS.

J Hepatol. 2013 May;58(5):949-55. doi: 10.1016/j.jhep.2013.01.003. Epub 2013 Jan 16.

13.

Targeting reduction of proteinuria in glomerulonephritis: Maximizing the antifibrotic effect of valsartan by protecting podocytes.

Gu C, Zhou G, Noble NA, Border WA, Cheung AK, Huang Y.

J Renin Angiotensin Aldosterone Syst. 2014 Jun;15(2):177-89. doi: 10.1177/1470320312466127. Epub 2012 Dec 4.

PMID:
23223090
14.

Asymmetric dimethylarginine is strongly associated with cognitive dysfunction and brain MR spectroscopic abnormalities in cirrhosis.

Bajaj JS, Ahluwalia V, Wade JB, Sanyal AJ, White MB, Noble NA, Monteith P, Fuchs M, Sterling RK, Luketic V, Bouneva I, Stravitz RT, Puri P, Kraft KA, Gilles H, Heuman DM.

J Hepatol. 2013 Jan;58(1):38-44. doi: 10.1016/j.jhep.2012.08.005. Epub 2012 Aug 11.

15.

Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation.

Bajaj JS, Hylemon PB, Ridlon JM, Heuman DM, Daita K, White MB, Monteith P, Noble NA, Sikaroodi M, Gillevet PM.

Am J Physiol Gastrointest Liver Physiol. 2012 Sep 15;303(6):G675-85. doi: 10.1152/ajpgi.00152.2012. Epub 2012 Jul 19.

16.

Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience.

Bajaj JS, O'Leary JG, Reddy KR, Wong F, Olson JC, Subramanian RM, Brown G, Noble NA, Thacker LR, Kamath PS; NACSELD.

Hepatology. 2012 Dec;56(6):2328-35. doi: 10.1002/hep.25947.

17.

Receptor-mediated nonproteolytic activation of prorenin and induction of TGF-β1 and PAI-1 expression in renal mesangial cells.

Zhang J, Wu J, Gu C, Noble NA, Border WA, Huang Y.

Am J Physiol Renal Physiol. 2012 Jul 1;303(1):F11-20. doi: 10.1152/ajprenal.00050.2012. Epub 2012 Apr 25.

18.

Combining angiotensin II blockade and renin receptor inhibition results in enhanced antifibrotic effect in experimental nephritis.

Zhang J, Gu C, Noble NA, Border WA, Huang Y.

Am J Physiol Renal Physiol. 2011 Oct;301(4):F723-32. doi: 10.1152/ajprenal.00271.2011. Epub 2011 Jul 27.

19.

Infusion of angiotensin-(1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis.

Zhang J, Noble NA, Border WA, Huang Y.

Am J Physiol Renal Physiol. 2010 Mar;298(3):F579-88. doi: 10.1152/ajprenal.00548.2009. Epub 2009 Dec 23.

20.

Mechanisms underlying the antifibrotic properties of noninhibitory PAI-1 (PAI-1R) in experimental nephritis.

Huang Y, Border WA, Lawrence DA, Noble NA.

Am J Physiol Renal Physiol. 2009 Oct;297(4):F1045-54. doi: 10.1152/ajprenal.00024.2009. Epub 2009 Jul 22.

21.

Receptor-dependent prorenin activation and induction of PAI-1 expression in vascular smooth muscle cells.

Zhang J, Noble NA, Border WA, Owens RT, Huang Y.

Am J Physiol Endocrinol Metab. 2008 Oct;295(4):E810-9. doi: 10.1152/ajpendo.90264.2008. Epub 2008 Jul 29.

22.

Aldosterone and TGF-beta1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells.

Huang W, Xu C, Kahng KW, Noble NA, Border WA, Huang Y.

Am J Physiol Renal Physiol. 2008 Jun;294(6):F1287-95. doi: 10.1152/ajprenal.00017.2008. Epub 2008 Mar 26.

23.

A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy.

Huang Y, Border WA, Yu L, Zhang J, Lawrence DA, Noble NA.

J Am Soc Nephrol. 2008 Feb;19(2):329-38. doi: 10.1681/ASN.2007040510. Epub 2008 Jan 23.

24.

PAI-1 as a target in kidney disease.

Huang Y, Noble NA.

Curr Drug Targets. 2007 Sep;8(9):1007-15. Review.

PMID:
17896952
25.

Functional renin receptors in renal mesangial cells.

Huang Y, Border WA, Noble NA.

Curr Hypertens Rep. 2007 Apr;9(2):133-9. Review.

PMID:
17442225
26.

Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells.

Huang Y, Noble NA, Zhang J, Xu C, Border WA.

Kidney Int. 2007 Jul;72(1):45-52. Epub 2007 Mar 28.

27.

Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis.

Huang Y, Border WA, Lawrence DA, Noble NA.

Kidney Int. 2006 Aug;70(3):515-22. Epub 2006 Jun 21.

28.

Perspectives on blockade of TGFbeta overexpression.

Huang Y, Border WA, Noble NA.

Kidney Int. 2006 May;69(10):1713-4.

29.

Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms.

Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, Noble NA, Border W.

Kidney Int. 2006 Jan;69(1):105-13.

30.
31.

Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect.

Yu L, Border WA, Anderson I, McCourt M, Huang Y, Noble NA.

Kidney Int. 2004 Nov;66(5):1774-84.

32.

Curcumin blocks multiple sites of the TGF-beta signaling cascade in renal cells.

Gaedeke J, Noble NA, Border WA.

Kidney Int. 2004 Jul;66(1):112-20.

33.

Genes expressed by the kidney, but not by bone marrow-derived cells, underlie the genetic predisposition to progressive glomerulosclerosis after mesangial injury.

Aben JA, Hoogervorst DA, Paul LC, Borrias MC, Noble NA, Border WA, Bruijn JA, de Heer E.

J Am Soc Nephrol. 2003 Sep;14(9):2264-70.

34.

TGF-beta isoforms in renal fibrogenesis.

Yu L, Border WA, Huang Y, Noble NA.

Kidney Int. 2003 Sep;64(3):844-56.

35.

A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis.

Huang Y, Haraguchi M, Lawrence DA, Border WA, Yu L, Noble NA.

J Clin Invest. 2003 Aug;112(3):379-88.

36.

L-arginine supplementation accelerates renal fibrosis and shortens life span in experimental lupus nephritis.

Peters H, Border WA, Rückert M, Krämer S, Neumayer HH, Noble NA.

Kidney Int. 2003 Apr;63(4):1382-92.

37.

Angiotensin II and progressive renal insufficiency.

Gaedeke J, Noble NA, Border WA.

Curr Hypertens Rep. 2002 Oct;4(5):403-7. Review.

PMID:
12217260
38.

Therapeutic strategies to halt renal fibrosis.

Yu L, Noble NA, Border WA.

Curr Opin Pharmacol. 2002 Apr;2(2):177-81. Review.

PMID:
11950630
39.

Angiotensin II, TGF-beta and renal fibrosis.

Gaedeke J, Peters H, Noble NA, Border WA.

Contrib Nephrol. 2001;(135):153-60. Review. No abstract available.

PMID:
11705280
40.

t-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis.

Haraguchi M, Border WA, Huang Y, Noble NA.

Kidney Int. 2001 Jun;59(6):2146-55.

41.
42.

Effect of maximal reduction of angiotensin in renal fibrosis: bad news-good news from a pediatric mouse.

Border WA, Noble NA.

Am J Kidney Dis. 2000 Apr;35(4):773-6. No abstract available.

PMID:
10739804
44.

Targeting TGF-beta overexpression: maximizing the antifibrotic actions of angiotensin II blockade in anti-Thy1 glomerulonephritis.

Peters H, Border WA, Noble NA.

Nephrol Dial Transplant. 1999;14 Suppl 4:22-3. No abstract available.

PMID:
10463199
45.

From rats to man: a perspective on dietary L-arginine supplementation in human renal disease.

Peters H, Border WA, Noble NA.

Nephrol Dial Transplant. 1999 Jul;14(7):1640-50. Review.

PMID:
10435871
46.
47.

Increased levels of transforming growth factor-beta in HIV-associated nephropathy.

Yamamoto T, Noble NA, Miller DE, Gold LI, Hishida A, Nagase M, Cohen AH, Border WA.

Kidney Int. 1999 Feb;55(2):579-92.

48.

Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis.

Isaka Y, Akagi Y, Ando Y, Tsujie M, Sudo T, Ohno N, Border WA, Noble NA, Kaneda Y, Hori M, Imai E.

Kidney Int. 1999 Feb;55(2):465-75.

49.
50.

Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy.

Border WA, Noble NA.

Kidney Int. 1998 Oct;54(4):1390-1. Review. No abstract available.

Supplemental Content

Loading ...
Support Center